| Literature DB >> 26090409 |
Minglan Li1, Clare M Reynolds1, Stephanie A Segovia1, Clint Gray1, Mark H Vickers1.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is fast becoming the most common liver disease globally and parallels rising obesity rates. The developmental origins of health and disease hypothesis have linked alterations in the early life environment to an increased risk of metabolic disorders in later life. Altered early life nutrition, in addition to increasing risk for the development of obesity, type 2 diabetes, and cardiovascular disease in offspring, is now associated with an increased risk for the development of NAFLD. This review summarizes emerging research on the developmental programming of NAFLD by both maternal obesity and undernutrition with a particular focus on the possible mechanisms underlying the development of hepatic dysfunction and potential strategies for intervention.Entities:
Mesh:
Year: 2015 PMID: 26090409 PMCID: PMC4450221 DOI: 10.1155/2015/437107
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1An overview of the development of NAFLD in the context of developmental programming. The developmental programming of NAFLD may occur secondarily to programmed obesity and/or via direct programming effects on the liver. Increased lipid accumulation and inflammation in liver can lead to NASH which is the severe form of NAFLD. NASH is associated with hepatic cirrhosis and HCC and carries a significantly increased mortality risk. NAFLD: nonalcoholic fatty liver disease, NASH: nonalcoholic steatohepatitis, HCC: hepatocellular carcinoma.
A summary of human and animal studies related to the developmental programming of NAFLD.
| Early life insults | Species | Offspring NAFLD | Influence on offspring adiposity | References |
|---|---|---|---|---|
| Maternal obesogenic environment | ||||
| Increased maternal BMI | Human | Increased neonatal hepatic lipid content | Independent of neonatal subcutaneous fat | [ |
| Maternal chronic HF diet consumption | NHP | Fetal hepatic steatosis persisting to juvenile age | No increase in body weight or body fat | [ |
| Maternal chronic HF diet consumption | Mouse | Hepatic steatosis in offspring with postweaning chow diet; NASH in offspring with postweaning HF diet | Increase in fat accumulation, with highest increase in offspring with postweaning HF diet | [ |
| Maternal HF diet | Mouse; rat | NASH in offspring with postweaning HF diet [ | Increased adiposity | [ |
| Maternal obesogenic diet (mixed source) | Mouse; rat | NASH in offspring with postweaning obesogenic diet [ | Increased body weight/adiposity [ | [ |
| HF diet induced maternal insulin resistance | NHP | NAFLD in offspring with postweaning chow diet | No obesity present | [ |
| Intergenerational HF diet | Mice | Progressive exacerbation of NAFLD | Progressively increased adiposity | [ |
| Growth restriction/maternal UN | ||||
| Low birth weight | Human | Increased plasma ALT and GCT at 60–79 years | Adjusted for waist-to-hip ratio | [ |
| Small for gestational age | Human | Independently associated with NAFLD | After correction for BMI | [ |
| Accelerated weight gain in the first 3 months of infancy | Human | Increased risk for NAFLD in early adulthood | After correction for adult weight | [ |
| Lean in early life and subsequently obese | Human | Increased risk for NAFLD | Adjusted for adult BMI | [ |
| Maternal low protein diet | Rat | Hepatic steatosis | Without a parallel increase in adiposity | [ |
| Maternal global nutrient restriction | Sheep | Hepatic lipid accumulation in aged offspring | Offspring are lean | [ |
| Maternal undernutrition | Rat | Fetal hepatic fat deposition at embryonic day 20 | Prior to the development of offspring adiposity | [ |
| Prenatal hypoxia induced IUGR | Rat | Hepatic steatosis in offspring with hypoxia challenge at age of 6 months | No change in body weight | [ |
| Vitamin B12 and folate deficiency induced IUGR | Rat | Hepatic steatosis at weaning | Significantly decreased body weight | [ |
Figure 2Potential mechanisms underlying the developmental programming of NAFLD. (1) Maternal obesity and high fat diet induced mitochondrial dysfunction may be programmed in the fetus; (2) maternal circulating lipids are shuttled to the fetal liver contributing to mitochondrial oxidative stress; this is characterised by reduced MRC activity, overproduction of ROS, and mitochondrial DNA damage. Increased concentrations of TAG and FFA contribute to ER stress which can induce additional oxidative stress, increase de novo lipogenesis, and activate inflammatory responses via JNK/NF-κB pathway. Lipid toxicity can active inflammation via TLR4 signalling pathway in both Kupffer cells and hepatocytes, where the former is a major source of proinflammatory cytokines including TNFα, IL1β, and IL6. Chronic low-level hepatic NF-κB activation further contributes to local and systemic insulin resistance, which in turn influences de novo lipogenesis. (3) Maternal undernutrition can reduce 11-β-hydroxysteroid dehydrogenase (11-β-HSD) in the placenta and therefore increase fetal exposure to maternal glucocorticoids. Increased glucocorticoids can lead to fetal de novo lipogenesis. Markers that indicate ER stress and de novo lipogenesis can be modified by early life epigenetic mechanism which may represent a path for intergenerational transmission of disease risk. MRC: mitochondrial respiratory chain; ROS: reactive oxygen species; TAG: triglyceride; FFA: free fatty acid; ER: endoplasmic reticulum; SREBP: sterol regulatory element binding protein; JNK: c-Jun N-terminal kinase; IKK: IκB kinase; NF-κB: nuclear factor kappaB; AP-1: activator protein 1; TLR4: Toll-like receptor 4; LXRα: Liver X receptor-α; PPARs peroxisome proliferator-activated receptors; ChREBP: carbohydrate-responsive element-binding protein; FASN: fatty acid synthase; SCD1: stearoyl-CoA desaturase-1; ACC1: acetyl-CoA carboxylase; 11-β-HSD: 11-β-hydroxysteroid dehydrogenase.